Patent application number | Description | Published |
20080286306 | HIV vaccines based on Env of multiple clades of HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 11-20-2008 |
20090208531 | ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA - These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies. | 08-20-2009 |
20090214588 | Vaccines against aids comprising cmv/r-nucleic acid constructs - The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided. | 08-27-2009 |
20090232841 | Optimzed vaccines to provide protection against ebola and other viruses - The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same. | 09-17-2009 |
20100068217 | EPITOPE-TRANSPLANT SCAFFOLDS AND THEIR USE - Computational protocols for the design of epitope-protein scaffolds which elicit selected neutralizing antibodies are disclosed, and related compositions and uses. | 03-18-2010 |
20100074916 | AVIAN INFLUENZA VACCINE - H5 hemagglutinin (HA) polypeptides are provided that are adapted to humans through mutations that change receptor specificity in the H1 serotype, and related polynucleotides, methods, compositions, and vaccines. | 03-25-2010 |
20100111998 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single Glade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 05-06-2010 |
20100297171 | DEVELOPMENT OF A PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN PRIMATES - The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus. | 11-25-2010 |
20100298414 | DEVELOPMENT OF A PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN PRIMATES - The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus. | 11-25-2010 |
20100303857 | DEVELOPMENT OF A PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN PRIMATES - The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus. | 12-02-2010 |
20110171260 | INFLUENZA DNA VACCINATION AND METHODS OF USE THEREOF - The present invention relates to an influenza immunogen that includes one or more DNA constructs encoding at least two divergent influenza HAs, wherein each of such one or more DNA constructs encodes one or more of the at least two divergent influenza HAs. Such an immunogen, when administered to a subject, induces an immune response to a plurality of strains of influenza virus, wherein at least one strain of the plurality of strains does not encode any of the divergent influenza HAs encoded by the immunogen. The divergent influenza HAs can be swine influenza HAs or equine influenza HAs, such as influenza H1 HAs or influenza H3 HAs. The invention also relates to a method to use such an immunogen to induce such an immune response as well as to DNA constructs comprising such divergent influenza HAs. Such an immunogen can provide a heterologous as well as a homologous immune response. Such an immunogen can be used to induce an immune response against evolving influenza virus. | 07-14-2011 |
20110200636 | METHOD FOR IMPROVING THE BREADTH OF THE IMMUNE RESPONSE TO DIVERSE STRAINS AND CLADES OF HIV - The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided. | 08-18-2011 |
20110274721 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 11-10-2011 |
20120034254 | ANTIGENIC CLOAKING AND ITS USE - Disclosed are antigens that include a target epitope that is defined by atomic coordinates of those amino acids of the antigen that contact an antibody of interest that specifically binds the antigen. The disclosed antigens have between about 10% and about 90% of surface exposed amino acid residues located exterior of the target epitope substituted as compared to a wild-type antigen and less than about 10% of the non-surface exposed amino acid residues substituted as compared to a wild-type antigen. Also disclosed are nucleic acids encoding these antigens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject. | 02-09-2012 |
20120156239 | OPTIMIZED VACCINES TO PROVIDE PROTECTION AGAINST EBOLA AND OTHER VIRUSES - The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same. | 06-21-2012 |
20120219583 | NUCLEIC ACID SEQUENCES ENCODING EXPANDABLE HIV MOSAIC PROTEINS - The invention is directed to a nucleic acid molecule encoding a HIV-1 polypeptide which comprises the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. The invention also provides a method of inducing an immune response against HIV-1 in a mammal. | 08-30-2012 |
20120219584 | PROTECTION AGAINST PANDEMIC AND SEASONAL STRAINS OF INFLUENZA - Immunogens and compositions are provided that encode a protein comprising an influenza A subtype H1 hemagglutinin glycan-shielded receptor binding domain A (RBD A) region and at least one influenza A subtype H1 hemagglutinin antigenic site wherein the antigenic site is not within the RBD-A region. Also provided are immunogens and compositions that encode an immunogenic protein comprising at least one epitope of the RBD-A region of a pandemic influenza A subtype H1 hemagglutinin antigen. Also provided are such proteins, nucleic acids that encode such proteins, and antibodies against such proteins. Also provided are methods to use such immunogens and compositions to elicit a neutralizing antibody immune response against influenza A subtype H1 virus. | 08-30-2012 |
20120237523 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes. | 09-20-2012 |
20120244166 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and uses of these antibodies, are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes. | 09-27-2012 |
20120282264 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes. | 11-08-2012 |
20130251726 | NOVEL HIV -1 BROADLY NEUTRALIZING ANTIBODIES - The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided. | 09-26-2013 |
20140322163 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed. | 10-30-2014 |